Skip to content

Mindfulness based cognitive therapy for recurrent depressive disorder

James McLoughlin, Paula Martin, Geraldine McCarthy, Chee Lin Piong

BJPsych Open June 1, 2021 DOI: 10.1192/bjo.2021.724 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Observational pre-post study Qualitative Peer reviewed
Sample size 19
Population Adults with a diagnosis of recurrent depressive disorder (primary or secondary) referred by community mental health teams
Intervention Mindfulness Based Cognitive Therapy (MBCT)
Duration 8-week programme, with data collected from four groups over twelve months
Measures Depression, Anxiety and Stress Scale (DASS), 5-Facet Mindfulness Questionnaire, Self-Compassion Scale
Topics Depression Meditation
Key findings Among 19 patients completing an 8-week MBCT course, depression and stress symptoms fell by 48% and 43% respectively (both statistically significant), while anxiety fell 26% but was not statistically significant. Mindfulness and self-compassion scores improved by 28.2% and 35.3%. The authors argue these results support greater use of MBCT as a non-pharmacological treatment for recurrent depressive disorder.

Abstract

Aims: Mindfulness-based therapies have been demonstrated to be effective in reducing anxiety, stress and depressive symptoms in adults. Depression is a chronic relapsing condition. Major depressive disorder is one of the most common causes of ill health and functional impairment. Our goal was to assess the real world clinical effectiveness of Mindfulness Based Cognitive Therapy (MBCT) for Recurrent Depressive Disorder in three domains: -Depression, anxiety and stress levels -Mindfulness level -Self-compassion level

Method: Patients with a diagnosis of Recurrent Depressive Disorder (primary or secondary diagnosis) were referred by their community mental health team to participate in an 8-week educational MBCT programme. Participants completed the Depression, Anxiety and Stress (DASS), 5-Facet Mindfulness and Self Compassion self-rated scales prior to commencing and at the end of the course. They were also invited to give qualitative feedback at the end of the course. Data were collected from four groups who completed the course over a period of twelve months. A paired samples test was used to compare pre and post intervention scores to determine effect size.

Result: We had complete data for 19 participants out of a cohort of 34. Pre intervention scores were similar for both groups. The mean age of the cohort was 47 years (SD of 10 years), 3 male, 16 female. Patients showed a clinically significant reduction of symptoms in depression, anxiety and stress, with respective reductions of 48%, 26% and 43% post intervention. Results were statistically significant for depressaion and stress p <0.001 but not for anxiety p = 0.130. Positive trends were seen in all domains of the 5-Fact Mindfulness and Self Compassions scales, with mean improvements of 28.2% and 35.3% respectively. All results were statistically significant. We also collected anonymized qualitative feedback which highlighted themes of empowerment, skill acquisition and improved coping.

Conclusion: Numerous studies have demonstrated poor compliance with antidepressant treatments commonly prescribed in Recurrent Depressive Disorder. This small scale study demonstrates a statistical and clinical benefit of MBCT for these patients, supporting greater use of such novel non-pharmacological therapeutic options as treatment strategies..

Comparable studies

Other non-randomized and open-label trials on depression, most cited first.

Study Year Design Participants
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Patients with moderate-to-severe, unipolar, treatment-resistant major depression 2016 Open-label feasibility trial n = 12
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Patients with severe, unipolar, treatment-resistant major depression 2017 Open-label trial n = 20
Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression 2018 Clinical trial n = 20
Rapid Resolution of Suicidal Ideation After a Single Infusion of anN-Methyl-D-Aspartate Antagonist in Patients With Treatment-Resistant Major Depressive Disorder Subjects with DSM-IV-diagnosed treatment-resistant major depressive disorder 2010 Open-label trial n = 33
Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Patients with recurrent depression 2015 Open-label trial n = 17

Citations in the library

Explore topics